A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections [clinicaltrials:NCT00360607]

Bio2RDF uri

A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections [clinicaltrials:NCT00360607]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00360607

Bio2RDF identifier

NCT00360607

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00360607

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00360607

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

307

http://www.w3.org/2001/XMLSchema#integer

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:5654d5a724964fae4b0b079d4366eaeb

brief summary [clinicaltrials_vocabulary:brief-summary]

Intra-abdominal infecti ...... sms found in such conditions.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

A Comparative Phase IV Study E ...... ) In Intraabdominal Infections

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Proportion of clinical efficacy-evaluable subjects who present with continued resolution at the 30-day follow-up visit. [clinicaltrials_resource:04b52b12580951327d7dce6082b7f16a]

Proportion of clinical efficacy-evaluable subjects who present with continued resolution at the 30-day follow-up visit. [clinicaltrials_resource:0ef1030734820f77d87beb0ee7b4413e]

Proportion of clinical efficacy-evaluable subjects who present with continued resolution at the 30-day follow-up visit. [clinicaltrials_resource:3c06f57e1d92b4342f06ffeab81c8229]

Proportion of clinical efficacy-evaluable subjects who present with continued resolution at the 30-day follow-up visit. [clinicaltrials_resource:8252db50b434d1bc93bc47ce926d5b38]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Proportion of clinical efficacy-evaluable subjects who present with continued resolution at the 30-day follow-up visit. [clinicaltrials_resource:7a113804c30437e8c224d39d0d7c428d]

Proportion of clinical efficacy-evaluable subjects who present with continued resolution at the 30-day follow-up visit. [clinicaltrials_resource:8cf36a6bc4088eefe7a5473fbd4393b1]

Proportion of clinical efficacy-evaluable subjects who present with continued resolution at the 30-day follow-up visit. [clinicaltrials_resource:9f20e789208a2453d158b577a382d1e2]

Proportion of clinical efficacy-evaluable subjects who present with continued resolution at the 30-day follow-up visit. [clinicaltrials_resource:aa2c47ac9eaa5a289269c9f7ad65cd98]

Proportion of clinical efficacy-evaluable subjects who present with continued resolution at the 30-day follow-up visit. [clinicaltrials_resource:e735e44290d6aef97c470b6194b65aca]

Proportion of clinical efficacy-evaluable subjects who present with continued resolution at the 30-day follow-up visit. [clinicaltrials_resource:ef913e881cfd1d71829ecb846c186b87]

completion date [clinicaltrials_vocabulary:completion-date]

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00360607 [clinicaltrials_resource:6117077eb6472691ef7f43bc891ff377]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2006-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd. [clinicaltrials_resource:27ac9ad35746942205409140b7c8da91]

Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited [clinicaltrials_resource:48d7e88b70a60aa11ccb24ef6abb48a3]

Magnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd. [clinicaltrials_resource:6e68985a3d3a29d524969a128cf27815]

Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd. [clinicaltrials_resource:c94de33ac16101ec063e23e62af15438]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Sulbactam [clinicaltrials_resource:4b713e32e9ceb822be4f6e5b39112045]

Cefoperazone [clinicaltrials_resource:7bfd051967326452e42edc690c138ec2]

Metronidazole [clinicaltrials_resource:a99c58cc988726a84729a4e3aa0394e2]

Ceftazidime [clinicaltrials_resource:af69930fceaecb38787969eeb5a3ba4e]

Amikacin [clinicaltrials_resource:be95777f1b249de1ac4b1b30415a53d5]

Sulperazone [clinicaltrials_resource:e52948f3e5a4a8f49f3e3b1ea6aa16df]

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Pfizer [clinicaltrials_resource:c1b9f1c2d5cc1361ccf28b0108bd7179]

link [clinicaltrials_vocabulary:link]

To obtain contact information for a study center near you, click here. [clinicaltrials_resource:bb7b730d38f27f430f42e65361fc1d7a]

location [clinicaltrials_vocabulary:location]

Pfizer Investigational Site [clinicaltrials_resource:a7854532ad1bd64ea673a8944cd90b8d]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00360607

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

A Randomized, Open Label, Mult ...... Of Intra-Abdominal Infections

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

A1891002

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Pfizer CT.gov Call Center [clinicaltrials_resource:7340297fe8931ae620f630868e86174a]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

India: Institutional Review Board [clinicaltrials_resource:dccb3b2dc9ef17455c69fcf492ce709c]

phase [clinicaltrials_vocabulary:phase]

Phase 4 [clinicaltrials_resource:ec41833bc88cd90619c4d85c549688bd]

responsible party [clinicaltrials_vocabulary:responsible-party]

Director, Clinical Trial Disclosure Group, Pfizer, Inc. [clinicaltrials_resource:757fb3099ae972f7f7ca50809082bbc0]

source [clinicaltrials_vocabulary:source]

Pfizer [clinicaltrials_resource:c1b9f1c2d5cc1361ccf28b0108bd7179]

start date [clinicaltrials_vocabulary:start-date]

2004-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00360607 study design [clinicaltrials_resource:35902a091173dabba82735dfc082c9d5]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00360607

verification date [clinicaltrials_vocabulary:verification-date]

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00360607

http://www.w3.org/2001/XMLSchema#string

title

A Comparative Phase IV Study E ...... ) In Intraabdominal Infections

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

A Comparative Phase IV Study E ...... s [clinicaltrials:NCT00360607]

@en